A61K 40/453
Clostridium
Official title: {Clostridium, e.g. Clostridium tetani}
A61K40/453 (Clostridium) appears on 24 US grants and 40 published applications in this corpus.
Search patents in A61K- Granted patents
- 24
- Published applications
- 40
- Assignees
- 38
- Inventors
- 91
- Latest grant
- 21 Nov 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 1 | 1 |
| 2003 | 1 | 1 |
| 2004 | 1 | 8 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 1 | 1 |
| 2008 | 1 | 4 |
| 2009 | 0 | 5 |
| 2010 | 0 | 1 |
| 2011 | 4 | 0 |
| 2012 | 2 | 3 |
| 2013 | 2 | 0 |
| 2014 | 1 | 2 |
| 2015 | 2 | 1 |
| 2016 | 1 | 2 |
| 2017 | 0 | 0 |
| 2018 | 1 | 2 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 2 |
| 2023 | 2 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nant cancer vaccine strategies21 Nov 2023US 11,823,773 B2Nant Holdings IP, LLC
- Tetanus toxoid and CCL3 improve DC vaccines27 Jun 2023US 11,684,662 B2Duke University
- Tetanus toxoid and CCL3 improve DC vaccines27 Jul 2021US 11,071,777 B2Duke University
- Tetanus toxoid and CCL3 improve DC vaccines22 May 2018US 9,974,848 B2Duke University
- Method for generating potent dendritic cells1 Mar 2016US 9,273,284 B2The Regents of the University of California
- Nanoparticles for delivery of immunoregulatory materials to t cells5 Mar 2026US 2026/0061054 A1The Johns Hopkins University
- Nant cancer vaccine strategies8 Feb 2024US 2024/0047009 A1Nant Holdings IP, LLC
- Bispecific antibody targeting of t regulatory cells for treatment of inflammatory conditions1 Sep 2022US 2022/0273718 A1University of Virginia Patent Foundation
- Tetanus toxoid and ccl3 improve dc vaccines3 Feb 2022US 2022/0031827 A1Duke University
- Selection and Cloning of T Lymphocytes in a Microfluidic Device16 Apr 2020US 2020/0115680 A1Berkeley Lights, Inc.
Most cited
By later US patents
- Mesenchymal stem cells as immunosuppressants110US 6,797,269 B2Osiris Therapeutics, Inc. · 2004
- Methods of generating antigen-specific CD4+CD25+regulatory T cells, compositions and methods of use55US 8,053,235 B2Benaroya Research Institute at Virginia Mason · 2011
- Activated dendritic cells and methods for their activation54US 6,017,527 AImmunex Corporation · 2000
- Method of stimulating an immune response with activated dendritic cells52US 6,497,876 B1Immunex Corporation · 2002
- Process for preparing dendritic cells, cells thus produced and containers for carrying out this process50US 5,866,115 AKlinikum Der Albert-Ludwigs-Universitat Freiburg · 1999